Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Laflamme, Michael A  [Clear All Filters]
2019
Romagnuolo R, Masoudpour H, Porta-Sánchez A, Qiang B, Barry J, Laskary A, Qi X, Massé S, Magtibay K, Kawajiri H, et al. Human Embryonic Stem Cell-Derived Cardiomyocytes Regenerate the Infarcted Pig Heart but Induce Ventricular Tachyarrhythmias. Stem Cell Reports. 2019.
2015
Posnack NGillum, Idrees R, Ding H, Iii RJaimes, Stybayeva G, Karabekian Z, Laflamme MA, Sarvazyan N. Exposure to Phthalates Affects Calcium Handling and Intercellular Connectivity of Human Stem Cell-Derived Cardiomyocytes. PLoS One. 2015;10(3):e0121927.
Kadota S, Carey J, Reinecke H, Leggett J, Teichman S, Laflamme MA, Murry CE, Regnier M, Mahairas GG. Ribonucleotide reductase-mediated increase in dATP improves cardiac performance via myosin activation in a large animal model of heart failure. Eur J Heart Fail. 2015.
2014
Shiba Y, Filice D, Fernandes S, Minami E, Dupras SK, Van Biber B, Trinh P, Hirota Y, Gold JD, Viswanathan M, et al. Electrical Integration of Human Embryonic Stem Cell-Derived Cardiomyocytes in a Guinea Pig Chronic Infarct Model. J Cardiovasc Pharmacol Ther. 2014.
Hartman ME, Liu Y, Zhu W-Z, Chien W-M, Weldy CS, Fishman GI, Laflamme MA, Chin MT. Myocardial deletion of transcription factor CHF1/Hey2 results in altered myocyte action potential and mild conduction system expansion but does not alter conduction system function or promote spontaneous arrhythmias. FASEB J. 2014.
Lundy SD, Gantz JA, Pagan CM, Filice D, Laflamme MA. Pluripotent stem cell derived cardiomyocytes for cardiac repair. Curr Treat Options Cardiovasc Med. 2014;16(7):319.